Navigation Links
Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
Date:3/22/2011

CAMBRIDGE, Mass., March 22, 2011 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that researchers will present pre-clinical data related to PVS-30200, the company's investigational cell therapy for the treatment of solid tumors, at a late-breaking oral presentation at the upcoming American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 in Orlando, Florida.

PVS-30200, which utilizes Pervasis' proprietary implantable material comprised of healthy allogeneic (donor) endothelial cells embedded in a polymer matrix, is designed to be administered locally to regulate processes involved in tumor growth and metastasis, including cell-proliferation, inflammation and invasion, in order to prevent the spread of cancer to secondary sites in the body. The well-studied patented technology on which PVS-30200 is founded has a proven safety profile as demonstrated by data from six clinical studies in the area of vascular repair.

Joseph Franses, from the Massachusetts Institute of Technology's (MIT) Division of Health Sciences and Technology, is the lead author of the abstract titled, "A first-in-class novel therapy (PVS-30200) for the treatment and prevention of metastatic cancer by regulating the tumor microenvironment," and will present the data at a Late-Breaking Research Session on Cancer Therapeutics and Epidemiology beginning at 3:00 p.m. on Tuesday, April 5, 2011 in Room W415 B/C (Vallencia Ballroom) at the Orange County Convention Center.

"We look forward to presenting PVS-30200 data at AACR and to having an opportunity to communicate the potential for this therapy to the oncology community," said Helen Marie Nugent, PhD, Co-Founder and Vice President, Research and Development at Pervasis and a co-author of the AACR abstract. "We are moving forward aggressively with our development program for PVS-30200 in order to deliver a safer, more effective treatment for solid tumors, preventing cancer recurrence and improvi
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
2. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
5. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
6. Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  TeamHealth Medical Call ... triage and nurse advice lines, announces its newly ... physician, nursing and administrative leaders, provides clinical expertise ... and cost-effective services for hospital clients, physician clients ... healthcare system evolves, it,s imperative to continuously advance ...
(Date:5/23/2013)... SANTA MONICA, Calif. , May 23, 2013 /PRNewswire-USNewswire/ ... of a program that would have required them to ... announced today by Consumer Watchdog and Whatley Kallas LLC.  ... San Diego Superior Court, alleged that Blue Cross,s mandatory ... HIV/AIDS patients, threatening their health and privacy. ...
(Date:5/23/2013)... MILFORD, Mass. , May 23, 2013  Spring ... for the treatment of viral infections, today announced that ... of SB 9200, its investigational, once daily, oral therapy ... conducted in healthy, HCV-infected patients and is designed to ... 9200. SB 9200 is a first-in-class drug for the ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
... the region,s premier provider of diagnostic imaging services, is ... Hospital Council of Western Pennsylvania,s newest business partner. ... the expertise of a large, highly-skilled team of imaging ... area. By partnering with FRG, community hospitals are able ...
... OAKS, Calif., Oct. 18 Amgen (Nasdaq: ... Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and ... of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) ... Administration,s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC). ...
Cached Medicine Technology:Hospital Council of Western Pennsylvania Announces Foundation Radiology Group as Newest Partner 2Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 2Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 3Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 4Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 5Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 6Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 7Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today 8
(Date:5/25/2013)... New York, New York (PRWEB) May 25, 2013 ... a federal multidistrict litigation underway in U.S. District Court, ... Liebhard LLP reports. According to a Case Management ... procedures that govern the filing of contested motions in ... for filing those motions. (In re: Actos Product Liability ...
(Date:5/25/2013)... May 25, 2013 Studies from Johns ... are carrying excessive weight and their inability to get ... simply losing weight can naturally relieve many symptoms. ... improvement in sleep quality was significantly associated with overall ... study dated November 6th, 2012, researchers monitored ...
(Date:5/25/2013)... York, NY (PRWEB) May 25, 2013 ... digestive problems, ranging from irritable bowel syndrome (IBS) ... problems are among the most long-lasting, embarrassing, frustrating ... natural foods for digestive health have ... While there are many factors contributing to digestive ...
(Date:5/25/2013)... UAE (PRWEB) May 25, 2013 Dr. ... LASIK surgery clinic in Dubai, has announced his practice’s ... laser is the only FDA-cleared femtosecond laser proven with ... the safety and precision of LASIK. , “We are ... iFS Advanced Femtosecond Laser at our Dubai LASIK practice,” ...
(Date:5/25/2013)... May 25, 2013 Prairie Living ... is hosting an American Red Cross Blood Drive from ... The community, which is located at 955 Villa Ct. ... including those on Medicaid, who need some help to ... of Life," says Andrea Arview Frey, Director of Marketing ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2
... , TUESDAY, Oct. 11 (HealthDay News) -- Environmental pollutants ... hardening of the arteries (atherosclerosis), according to a new ... cardiovascular diseases, which are the most common cause of ... University in Sweden. They measured levels of persistent ...
... have identified cells and signaling molecules that trigger the ... his colleagues report October 10, 2011, online in the ... lung tissue in mice induces smooth muscle cells surrounding ... growth factor 10 (FGF10), which induces surviving epithelial cells ...
... Reserve University School of Medicine and the Case ... receipt of a highly competitive $5.4 million grant ... esophageal adenocarcinoma. This five-year award from the National ... Research Network (BETRNet), which consists of multiple centers ...
... medications, including antidepressants, antihistamines, bronchodilators, anticholinergics, sympathomimetics, and ... tract symptoms among men according to a Kaiser ... Internal Medicine . This study demonstrates an ... drugs and LUTS among men enrolled in the ...
... Society for Radiation Oncology (ASTRO), the Association of Residents ... the 2011 Educator of the Year Award. , ARRO ... recognize outstanding teachers and mentors of radiation oncology residents. ... opportunity to select one faculty member from their program ...
... as herbal supplements have become increasingly popular in the ... chronic pain. However, many of these products can have ... medications prescribed during and after surgery, according to a ... American Academy of Orthopaedic Surgeons (JAAOS). , ...
Cached Medicine News:Health News:Environmental Toxins Linked to Hardening of Arteries 2Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 2Health News:Case Western Reserve receives prestigious $5.4 million grant to study esophageal cancer 3Health News:Common medications can contribute to lower urinary tract symptoms in men 2Health News:ARRO honors 39 with Educator of the Year Award 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 2Health News:Herbal supplements may cause dangerous drug interactions in orthopaedic surgery patients 3
... PDC Smart™ Labels have a direct ... Texas Instruments Tag-it™ HF-I transponder. When ... codes, text and other graphics may ... variable data is programmed to the ...
The PDC Smart® Key Fob can be programmed on demand using a 13.56 MHz RFID reader/writer and is ideal for long-term use applications such as electronic access control or loyalty programs....
... SURGICHIP™ is a patent pending ... technology embedded in a smart label ... to prevent wrong-patient, wrong-site, wrong-procedure surgery. ... developed by an orthopedic surgeon with ...
... are carefully crafted with the highest ... SATO Techno THERM RFID labels are ... optimum performance in your SATO printer ... are available in HF and UHF ...
Medicine Products: